

Overview

Useful For

Detecting drug use involving amphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, phencyclidine, and tetrahydrocannabinol

This chain-of-custody test is intended to be used in a setting where the test results can be used to make a definitive diagnosis.

Profile Information

Test Id	Reporting Name	Available Separately	Always Performed
PN10X	Pain Clinic Survey 10, CoC	No	Yes
OXYSX	Oxycodone Screen, CoC, U	Yes	Yes

Reflex Tests

Test Id	Reporting Name	Available Separately	Always Performed
AMPHX	Amphetamines Confirmation, CoC, U	Yes	No
COKEX	Cocaine and metabolite Conf, CoC, U	Yes	No
BARBX	Barbiturates Confirmation, CoC, U	Yes	No
MTDNX	Methadone Confirmation, CoC, U	Yes	No
PCPX	Phencyclidine Confirmation, CoC, U	Yes	No
THCX	Carboxy-THC Confirmation, CoC, U	Yes	No
OPATX	Opiate Confirmation, CoC, U	Yes	No
OXYCX	Oxycodone w/metabolite Conf, CoC, U	Yes	No
BNZX	Benzodiazepines Conf, CoC, U	Yes	No

Additional Tests

Test Id	Reporting Name	Available Separately	Always Performed
COCH	Chain of Custody	No	Yes

	Processing		
ADLTX	Adulterants Survey, CoC, U	Yes	Yes

Testing Algorithm

If immunoassay screen is positive, then gas chromatography-mass spectrometry (GC-MS) confirmation is performed. GC-MS confirmation with quantification of positives for amphetamines, barbiturates, benzodiazepines, cocaine and metabolites, methadone, phencyclidine, and tetrahydrocannabinol metabolite will be performed at an additional charge.

Adulterants testing will be performed on all chain of custody urine samples as per regulatory requirements.

Method Name

Screened by Immunoassay and Confirmed by Gas Chromatography-Mass Spectrometry (GC-MS)

NY State Available

Yes

Specimen

Specimen Type

Urine

Specimen Required

Container/Tube: Chain-of-Custody Kit (T282) containing the specimen containers, seals, and documentation required.

Specimen Volume: 30 mL

Collection Instructions: Collect a random specimen in the container provided, seal, and submit with the associated documentation to satisfy the legal requirements for chain-of-custody testing.

Additional Information: Submitting less than 30 mL will compromise our ability to perform all necessary testing.

Forms

- [1. Chain of Custody Request](#) is included in the Chain-of-Custody Kit (T282).
- If not ordering electronically, complete, print, and send a [Therapeutics Test Request](#) (T831) with the specimen.

Specimen Minimum Volume

20 mL

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Urine	Refrigerated (preferred)	7 days	

	Frozen	14 days	
--	--------	---------	--

Clinical & Interpretive

Clinical Information

This assay was designed to test for and confirm by gas chromatography-mass spectrometry (GC-MS) the following:

- Barbiturates
- Benzodiazepines
- Cocaine
- Methadone
- Phencyclidine
- Tetrahydrocannabinol

Confirmation by liquid chromatograph-tandem mass spectrometry (LC-MS/MS) is completed for all opiates and amphetamines.

This test uses the simple screening technique which involves immunologic testing for drugs by class. Oxycodone is not detected well with the opiate screening assay; therefore, OPATX / Opiate Confirmation, Chain of Custody, Urine is included to detect this drug. All positive screening results are confirmed by GC-MS or LC-MS/MS, and quantitated, before a positive result is reported.

Chain of custody is a record of the disposition of a specimen to document who collected it, who handled it, and who performed the analysis. When a specimen is submitted in this manner, analysis will be performed in such a way that it will withstand regular court scrutiny. Chain of custody is required whenever the results of testing could be used in a court of law. Its purpose is to protect the rights of the individual contributing the specimen by demonstrating that it was under the control of personnel involved with testing the specimen at all times; this control implies that the opportunity for specimen tampering would be limited.

Reference Values

- Negative
- Screening cutoff concentrations
- Amphetamines: 500 ng/mL
- Barbiturates: 200 ng/mL
- Benzodiazepines: 100 ng/mL
- Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
- Methadone metabolite: 300 ng/mL
- Opiates: 300 ng/mL
- Phencyclidine: 25 ng/mL
- Tetrahydrocannabinol carboxylic acid: 50 ng/mL

This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.

Interpretation

A positive result derived by this testing indicates that the patient has used 1 of the drugs detected by these techniques in the recent past. See individual tests (eg, AMPHU / Amphetamines Confirmation, Urine) for more information.

For information about drug testing, including estimated detection times, see [Drugs of Abuse Testing](#).

Cautions

Not intended for use in employment-related testing.

The test does not screen for drug classes other than those listed above. More comprehensive screening is available using the serum or urine drug screens (DSSX / Drug Screen, Prescription/OTC, Chain of Custody, Serum or PDSUX / Drug Screen, Prescription/OTC, Chain of Custody, Urine).

Clinical Reference

1. Physician's Desk Reference (PDR). 60th edition. Montvale, NJ, Medical Economics Company, 2006
2. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th edition. Edited by LL Bruntman. New York, McGraw-Hill Book Company, 2006
3. Langman LJ, Bechtel L, Holstege CP: Chapter 35. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Edited by CA Burtis, ER Ashwood, DE Bruns. WB Saunders Company, 2011, pp 1109-1188

Performance**Method Description**

The amphetamines, barbiturates, benzodiazepines, cocaine, methadone metabolite, opiates, phencyclidine, and tetrahydrocannabinol metabolite assays are based on the kinetic interaction of microparticles in a solution (KIMS) as measured by changes in light transmission. In the absence of sample drug, soluble drug conjugates bind to antibody-bound microparticles causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases. When a urine sample contains the drug in question, this drug competes with the drug derivative conjugate for microparticle-bound antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug. (Package insert: Roche Amphetamines, Barbiturates, Cannabinoids, Benzodiazepines, Cocaine, Opiates, Oxycodone, Phencyclidine, reagents, Roche Diagnostic Corp, Indianapolis, IN; Package insert: EDDP Specific Urine Enzyme Immunoassay, Immulysis Corp, Pomona, CA)

PDF Report

No

Day(s) Performed

Monday through Saturday

Report Available

2 to 3 days

Specimen Retention Time

2 weeks

Performing Laboratory Location

Rochester

Fees & Codes

Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

80307

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
PANOX	Pain Clinic Survey 10, CoC, U	69739-1

Result ID	Test Result Name	Result LOINC® Value
36253	Amphetamines	43983-6
36254	Cocaine	43984-4
36255	Opiates	70151-6
36256	Phencyclidine	14310-7
36257	Tetrahydrocannabinol	14312-3
36261	Chain of Custody	77202-0
36258	Barbiturates	70155-7
36259	Benzodiazepines	14316-4
36260	Methadone metabolite	41858-2
61727	Oxycodone	19642-8
36027	Chain of Custody	77202-0